Top Healthcare Stock Losers (DNDN, THOR, HGSI, INCY)
Dendreon Corporation (NASDAQ:DNDN) dropped 3.27% to $38.47 on about 2.90 million shares. Canaccord Genuity maintained a 'Buy' on Dendreon with a price target of $60.
Over the past 52-week, the stock had traded within the range of $24.79-$57.67 and is up more than 46% year-to-date.
Thoratec Corporation (NASDAQ:THOR) lost 4.59% to $33.64 on about 3.80 million shares. Thoratec Corporation is a manufacturer of mechanical circulatory support products for use by patients with heart failure (HF). The Company develops, manufactures and markets products that are used by physicians and hospitals for cardiac assist, vascular and diagnostic applications.
The stock opened at $33.93 and is trading within the range of $32.69- $34.18. In the past one month of trading sessions, the stock went down more than 3%.
Human Genome Sciences (NASDAQ:HGSI) fell 4.87% to $27.34 on over 3.19 million shares. Human Genome Sciences is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: BENLYSTA for systemic lupus erythematosus (SLE), ZALBIN for chronic hepatitis C, and raxibacumab for inhalation anthrax.
The stock opened at $28.87 and has a 52-week range of $17.83-$34.49.
Incyte Corporation (NASDAQ:INCY) declined 1.51% to $16.91 after it created its new one-year high of $17.40. Incyte Corporation is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs.
Over the past 52-week, the stock had traded within the range of $5.30-$17.40 and is up more than 82% year-to-date.
To get up to date market moving news please visit the Wall Street Grand blog at www.wallstreetgrand.com. Wall Street Grand is a leading online Financial Newsletter who specializes in finding undervalued and undiscovered stocks. Visit the Wall Street Grand Club today and Join Free by clicking the SAFE LINK.
Disclaimer:
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. Never invest into a stock we discuss unless you are prepared to lose your entire investment. WSG has not been compensated for this press release and does not own any of the stocks mentioned in this release. To read our full detailed disclaimer on each stock please visit our profiles page at wall street grand and scroll to the bottom of each profile. WSG may or may not trade the stocks mentioned in this alert which can affect the price of the stock The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
